David Mushatt MD, MPH&TM, FIDSA, FACP

Professor of Medicine

Section Chief
School of Medicine
David Mushatt, MD, MPH


Dr. Mushatt received his medical degree in 1986 from Harvard Medical School. He completed his internal medicine residency training from 1986 - 1989 at the Harvard-affiliated Brigham and Women’s Hospital in Boston, and then did an Infectious Diseases Fellowship at Tulane University School of Medicine from 1989 – 1991. During the second year of his ID fellowship, he also earned an MPH in Tropical Medicine (MPH&TM) at the Tulane School of Public Health and Tropical Medicine.

Dr. Mushatt joined the Tulane ID Section immediately after fellowship, starting out as an Assistant Professor in 1991, and later became Director of the ID Fellowship Program in 2002 and was promoted to Chief of the Section in 2006.

Dr. Mushatt is Principal Investigator of the Louisiana Community AIDS Research Program, the Tulane clinical trials site that was formerly part of the CPCRA and now part of INSIGHT, an NIH-funded international HIV research group that focuses on strategies in HIV treatment at the community level.

Dr. Mushatt enjoys teaching students, residents and fellows and received the Best Subspecialty Attending Award from the Medicine Residency Program in 2008.


Mushatt DM and Hyslop NE Jr.:  Neurologic aspects of North American zoonoses.  Infect Dis Clin North Amer 1991; 5:703-731.

Mushatt DM and Witzig RS:  Successful treatment of Mycobacterium abscessus infections with multidrug regimens containing clarithromycin.  Clin Infect Dis 1995; 20:1441-2.

Witzig RS, Fazal BA, Mera RM, Mushatt DM, et al.:  Clinical manifestations and implications of coinfection with Mycobacterium kansasii and human immunodeficiency virus type 1.  Clin Infect Dis 1995; 21:77-85.

Hafner R, Bethel J, Power M, Landry B, Banach M, Mole L, Standiford H, Follansbee S, Kumar P, Raasch R, Cohn D, Mushatt D, and Drusano G: Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. Antimicrob Agents Chemother 1998; 42:631-39

Mzayek F, Deng H, Mather F, Wasilevich E, Liu H, Hadi C, Chansolme D, Murphy H, Melek B, Tenaglia A, Mushatt D, Dreisbach A, Lertora J, Krogstad D: Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clinical Trials 2007; 2:e6 DOI: 10.1371/journal.pctr.0020006.

Mushatt D, Mihm L, Dreisbach A, Simon E: Antibiotic dosing in slow extended daily dialysis. Clin Infect Dis 2009; 49: 433-7.

Lantos PM, Charini WA, Medoff G, Moro MH, Mushatt DM, Parsonnet J, Sanders JW, Baker CJ: Final report of the Lyme disease review panel of the Infectious Diseases Society of America. Clin Infect Dis 2010; 51:1-5.

Mave V, Gahunia M, Frontini M, Clark R, Mushatt D: Gender differences in HIV drug resistance mutations and virologic outcome. J Womens Health 2011; 20:1-6.

Luis Ostrosky-Zeichner, Shmuel Shoham, Jose Vazquez, Annette Reboli, Robert Betts, Michelle A. Barron, Mindy Schuster, Marc A. Judson, Sanjay G. Revankar, Juan Pablo Caeiro, Julie E. Mangino, David Mushatt, Roger Bedimo, Alison Freifeld, Minh Hong Nguyen, Carol A. Kauffman, William E. Dismukes, Andrew O. Westfall, Jeanna Beth Deerman, Craig Wood, Jack D. Sobel, and Peter G. Pappas: MSG-01: A randomized, double-blind, placebo controlled trial of caspofungin prophylaxis followed by pre-emptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis 2014; 58:1219-26.

Salerno D, Mushatt D, Myers L, Zhuang Y, de la Rua N, Calderon E, Welsh D. Serum and BAL beta-D-glucan for the diagnosis of Pneumocystis pneumonia in HIV positive patients.  Respir Med 2014; 108:1688-95.

Dr. Mushatt’s main research interest is HIV clinical trials. His clinical interests are in HIV medicine, fungal and mycobacterial infections, orthopedic infections and zoonoses. Other interests include human research subjects protections, having served as Vice-Chairman of the Tulane IRB, and the doctor-patient relationship.